|
|
WuXi PharmaTech Surprises with a 5% Q1 Revenue Increase
publication date: May 15, 2009
WuXi PharmaTech (药明康德) announced a 5% increase in Q1 revenues, but net income fell 15% and earnings per share dropped an even-greater 22% during the period. Stressing the positive, WuXi said its core business, China CRO laboratory services, rose a healthy 33%. The problem was in contract manufacturing, whose revenues sank by 81%. Evidently, WuXi has done a good job of preparing Wall Street for even worse results, because shares of WuXi moved sharply higher following the earnings announcement. More details... Stock Symbol: (NYSE: WX)
|
ChinaBio® Events
April 14, 2010 Guangzhou, China Suzhou, China June 23-24, 2010
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners
![]()
|